Quality of life in allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 83, Issue 5, 1999, Pages 449-454

  Blaiss, Michael S ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIPHENHYDRAMINE; FEXOFENADINE; FLUTICASONE; IPRATROPIUM BROMIDE; LORATADINE; PSEUDOEPHEDRINE; TERFENADINE; TRIAMCINOLONE ACETONIDE;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; INTRANASAL DRUG ADMINISTRATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0032725724     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62850-5     Document Type: Article

References (30)

1. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax 1991;46:895-901.
2. Ellwood PM. Shattuck lecture-outcomes management: a technology of patient experience. N Engl J Med 1988;318:1549-1556.
3. Davies A, Doyle M, Lansky D. Outcomes assessment in clinical settings: a consensus statement on principles and best practices in project management. J Quality Improvement 1994;20: 6-16.
4. Donabedian A. The role of outcomes in quality assessment and assurance. QRB 1992;5:356-360.
5. Organization WH. Constitution of the World Health Organization. Basic Documents. Geneva, Switzerland; 1948.
6. Spiker B. Quality of life assessments in clinical trials. New York: Raven Press, 1990.
7. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-840.
8. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30: 473-483.
9. Ware JE, Kosinski M, Keller SD. A 12-item short form health survey construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
10. Bergner M, Bobbit RA, Carter WB. The sickness impact profile: development and final revision of a health status measure. Med Care 1981;9: 787-805.
11. Hunt S, McEwen J, McKenna S. Measuring health status. Beckenham: Croom Helm, 1986.
12. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 1994;94:182-188.
13. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99:S742-749.
14. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81-87.
15. de Graaf in 't Veld T, Koenders S, Garrelds IM, Gerth van Wijk R. The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis. J Allergy Clin Immunol 1996; 98:508-513.
16. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-423.
17. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309-316.
18. Harvey RP, Comer C, Sanders B, et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97:1233-1241.
19. Tanner A, Reilly M, Meltzer E. Evaluation of quality of life and health economic measures in patients treated with fexofenadine HCl for seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;78:125.
20. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. J Allergy Clin Immunol 1997; 100:781-788.
21. Juniper EF, Guyatt GH, Andersson B, Ferrie PJ. Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire. Ann Allergy 1993; 70:225-230.
22. Juniper EF, Guyatt GH, Archer B, Ferrie PJ. Aqueous beclomethasone dipropionate in the treatment of ragweed pollen-induced rhinitis: further exploration of "as needed" use. J Allergy Clin Immunol 1993;92:66-72.
23. Kaiser HB, Findlay SR, Georgitis JW, et al. Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06%. J Allergy Clin Immunol 1995;95:1128-1132.
24. Meltzer EO, Orgel HA, Biondi R, et al. Ipratropium nasal spray in children with perennial rhinitis. Ann Allergy Asthma Immunol 1997;78:485-491.
25. Goodwin B, Bowers B, Hampel F. Superior improvement in disease-specific quality of life for SAR patients receiving intranasal fluticasone vs loratadine tablets. J Allergy Clin Immunolo 1997; 99:S270.
26. Schultz R, Lim J. Quality of life in patients with seasonal allergic rhinitis: triamcinolone acetonide aqueous nasal spray versus loratadine. Ann Allergy Asthma Immunol 1997;78:155.
27. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. First-line treatment of seasonal (ragweed) rhinoconjunctivitis. A randomized management trial comparing a nasal steroid spray and a nonsedating antihistamine [see comments]. Can Med J 1997;156:1123-1131.
28. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71: 121-126.
29. Vuurman E, van Veggel L, Sanders R. Effects of Semprex-D and diphenhydramine on learning in young adults with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1996;76: 247-252.
30. Borres M, Brakenhielm G, Irander K. How many teenagers think they have allergic rhinoconjunctivitis and what they do about it. Ann Allergy Asthma Immunol 1997;78:29-34.